Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Vivus ( VVUS) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Vivus rose 32 cents (2.9%) to $11.42 on average volume. Throughout the day, 4.6 million shares of Vivus exchanged hands as compared to its average daily volume of 4.4 million shares. The stock ranged in a price between $11.12-$11.74 after having opened the day at $11.12 as compared to the previous trading day's close of $11.10. Other companies within the Health Care sector that increased today were: Affymax ( AFFY), up 53.7%, Durect Corporation ( DRRX), up 16.4%, Opexa Therapeutics ( OPXA), up 14.4%, and Northwest Biotherapeutics ( NWBO), up 12.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

VIVUS, Inc., a biopharmaceutical company, is developing therapies to address obesity, sleep apnea, diabetes, and male sexual health. Its lead investigational product, Qnexa, has completed Phase three clinical trials for the treatment of obesity. Vivus has a market cap of $1.05 billion and is part of the drugs industry. Shares are down 22.2% year to date as of the close of trading on Wednesday. Currently there are six analysts that rate Vivus a buy, two analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Vivus as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself.

On the negative front, Inovio Pharmaceuticals ( INO), down 24.6%, Oculus Innovative ( OCLS), down 20.4%, Escalon Medical Corporation ( ESMC), down 11.4%, and CytRx Corporation ( CYTR), down 10.5%, were all laggards within the health care sector with Perrigo Company ( PRGO) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.